BANCOR
11.5.2022 15:02:06 CEST | Business Wire | Press release
Bancor (BNT) , the inventor of DeFi and liquidity pools, has announced its new protocol version, Bancor 3, is now live. Bancor 3 is set to be the ultimate automated DeFi liquidity solution empowering token projects and their holders to drive healthy on-chain liquidity in their native tokens.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220506005455/en/
The launch has already attracted 30+ token projects and DAOs including Polygon (MATIC), Synthetix (SNX), Brave (BAT), Flexa (AMP), Yearn (YFI), Enjin (ENJ), WOO Network (WOO) and Nexus Mutual (wNXM), which are providing seed liquidity on the network or offering liquidity incentives via Bancor’s new customizable Auto-Compounding Rewards system.
Token projects and DAOs can use Bancor to:
- Maintain liquid markets for their native token, facilitating cheaper token trading.
- Enable token holders to earn safer, higher yields exclusively in their native token (Single-Sided Staking with 100% Impermanent Loss Protection).
- Deploy Auto-Compounding Rewards that minimize sell pressure and are simultaneously used as fee-generating liquidity from day one.
Driving Sustainable Liquidity in DeFi
Decentralized liquidity is the backbone of DeFi, yet strategies employed by token projects to create long-term liquidity have proven ineffective. Due to the risk of negative returns from Impermanent Loss, most token holders today are reluctant to provide their tokens to liquidity pools. Meanwhile, liquidity mining rewards programs largely end up in the hands of “mercenary yield farmers” who hop from pool to pool liquidating earned rewards into their preferred asset, leaving the token projects high and dry.
Roughly two years after yield farming burst onto the scene and spawned the first “DeFi Summer” in 2020, DAOs and token communities are still searching for a safe, simple and sustainable way to drive decentralized liquidity.
Today, Bancor launches out of beta its new and improved third version, aimed at creating sustainable on-chain liquidity for token projects by giving participants access to Single-Sided Staking with no risk of Impermanent Loss, and providing them with Auto-Compounding and Dual Rewards. Liquidity providers are less likely to withdraw liquidity when rewards expire since they’re always protected from value loss and can earn with zero maintenance.
Bancor 3: The Ultimate DeFi Liquidity Solution
Bancor 3 introduces novel features that encourage broad and sustainable involvement in on-chain liquidity markets by dramatically simplifying passive liquidity provision in automated market-maker (AMM) liquidity pools. Key features include:
- Omnipool : A new protocol architecture that consolidates token liquidity in a single, virtual vault, minimizing gas costs and increasing efficiency and usability at every touchpoint.
- Unlimited Single-Sided Staking : Provide liquidity and earn yield in a single token; no need to pair 50/50 or buy another asset.
- Auto-Compounding Earnings: Trading fees and rewards auto-compound with zero transaction fees, and are simultaneously used as liquidity inside the pool from day one. Auto-compounding is optimized via an integration with Chainlink Keepers.
- Instant Protection: All deposited tokens receive 100% Impermanent Loss Protection instantly.
- Single-Sided Pool Tokens : The first-ever fungible Single-Sided Pool Tokens. Unlike normal Pool Tokens, Single-Sided Pool Tokens only rise relative to their underlying assets, creating a new kind of “up only” money lego that is easily composable in other DeFi products.
- Smart Portfolio : A new front-end interface gives full transparency into actual net earnings on deposited tokens.
- Dual Rewards: Third-party token projects can now incentivize liquidity on Bancor with auto-compounding rewards free from Impermanent Loss.
- Revamped Tokenomics: New BNT tokenomics create a more cost-efficient system for directing protocol liquidity to the highest-earning liquidity pools.
Mark Richardson, Product Architect at Bancor (BNT) , said:
“Bancor has spent the past several years creating the equivalent of a high-yield savings account for DeFi: Deposit your assets, sit back and earn. By helping token projects and their users safely and simply tap into DeFi yields, Bancor 3 creates robust and resilient on-chain liquidity markets that drive healthy token economies.”
Hamzah Khan, Head of DeFi and Labs at Polygon (MATIC) , said:
“Polygon is excited to utilize Bancor 3 to build decentralized liquidity for MATIC token holders. Bancor’s single-sided liquidity and impermanent loss protection mechanisms make it easier for our DAO and token holders to safely stake and earn MATIC, while driving community-sourced liquidity that powers low-slippage MATIC trading.”
Tyler Spalding, Co-founder of Flexa (AMP) , said:
“Bancor has become one of the largest sources of on-chain AMP liquidity for a reason: It is a safe and simple way to stake. With Bancor 3, we’re doubling down on our belief in Bancor by providing auto-compounding rewards to our token holders who stake their AMP on Bancor.”
Useful links:
About Bancor Protocol
Bancor is the only DeFi trading and staking protocol with Single-Sided Liquidity & 100% Impermanent Loss Protection. Overseen by the Bancor DAO, the protocol's mission is to bring DeFi mainstream by providing the simplest and safest way to trade tokens and earn passive income in DeFi.
Launched in 2017, Bancor was the first DeFi protocol. Today, it generates millions in fees per month for depositors, offering up to 30% APR on 150+ tokens like ETH, WBTC, LINK, MATIC, AMP, SNX & more. Bancor is the preferred treasury management solution of 30+ DAOs including Polygon, Nexus Mutual, UMA, KeeperDAO & WOO Network DAO.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220506005455/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom